Giovanna Amaral

Ms. Giovanna Amaral

UNIFESP

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Ramon Andrade Bezerra De MelloRamon Andrade Bezerra De Mello
Ramon Andrade Bezerra De Mello
NNNathália Moisés Neves
Nathália Moisés Neves
HTHakaru Tadokoro
Hakaru Tadokoro
Giovanna AmaralGiovanna Amaral
Giovanna Amaral
PBPedro Castelo Branco
Pedro Castelo Branco
VZVictor André de Almeida Zia
Victor André de Almeida Zia
Introduction: Lung cancer (LC) is the most common neoplasm worldwide, and 85% of these tumors are classified as non-small cell lung cancer (NSCLC). LC treatment was initially restricted to cytotoxic chemotherapy—platinum compounds associated with 3rd generation cytotoxic agents (paclitaxel, gemcitabine, pemetrexed) and, more recently, with monoclonal antibodies (bevacizumab, ramucirumab). Advancements in treatment are correlated with prolonged overall survival (OS). Current advances are focused on target therapies. Target agents: Anti-epidermal growth factor receptor (EGFR) therapy consists of 1st and 2nd generation tyrosine kinase inhibitors (TKIs such as erlotinib, afatinib). In 60% of cases, resistance to these TKIs occurs due to T790M mutation in EGFR, which is overcome 3rd generation drugs (osimertinib). Anaplastic lymphoma kinase (ALK) is the target for drugs such as crizotinib, alectinib, ceritinib. Programmed death 1 (PD-1) and its ligand serve as targets for immunotherapy agents such as pembrolizumab, nivolumab, atezolizumab. Discussion: Challenges in NSCLC treatment include resistance to 3rd generation TKIs, the high cost of ALK inhibitors, and the need for further research on new drugs.

22 July 2021 in Future Oncology
Verified
Journal Article
Closed access
Ramon Andrade Bezerra De MelloRamon Andrade Bezerra De Mello
Ramon Andrade Bezerra De Mello
Giovanna AmaralGiovanna Amaral
Giovanna Amaral
NNNathália Moisés Neves
Nathália Moisés Neves
ELEstela Gudin Lippo
Estela Gudin Lippo
FPFernanda Parini
Fernanda Parini
JZJinhui Zhu
Jinhui Zhu
Gastric cancer is the fourth most common type of cancer worldwide and the second most lethal. Gastric cancer biomarkers can be used for diagnosis, prediction of sensitivity to treatment, and prognosis. The following search terms were applied to PubMed as of December 2020: 'gastric cancer classification', 'gastric cancer epidemiology', 'cancer metastasis' and 'gastric cancer biomarker'. Only experimental studies were reported in the 'biomarkers' section. Some biomarkers can serve as therapeutic targets for antitumoral drugs. The genes analyzed include E-cadherin, RPRM, XAF1, MINT25, TFF1, p16 and p53. The miRNAs analyzed include miR-18a, miR185-5p, miR-125b and miR-21. Some molecules were associated with metastasis of gastric cancer, specifically those involved with EMT process and tissue degradation.

Verified
Journal Article
Open access
PDF file
Ramon Andrade Bezerra De MelloRamon Andrade Bezerra De Mello
Ramon Andrade Bezerra De Mello
NNNathália Moisés Neves
Nathália Moisés Neves
Giovanna AmaralGiovanna Amaral
Giovanna Amaral
ELEstela Gudin Lippo
Estela Gudin Lippo
PBPedro Castelo Branco
Pedro Castelo Branco
GAGeorgios Antoniou
Georgios Antoniou
Introduction: Non-small cell lung cancer (NSCLC) is the second most common cancer globally. The mesenchymal-epithelial transition (MET) proto-oncogene can be targeted in NSCLC patients. Methods: We performed a literature search on PubMed in December 2019 for studies on MET inhibitors and NSCLC. Phase II and III clinical trials published in English between 2014 and 2019 were selected. Results: Data on MET inhibitors (tivantinib, cabozantinib, and crizotinib) and anti-MET antibodies (emibetuzumab and onartuzumab) are reported in the text. Conclusion: Emibetuzumab could be used for NSCLC cases with high MET expression. Further, studies on onartuzumab failed to prove its efficacy, while the results of tivantinib trials were clinically but not statistically significant. Additionally, cabozantinib was effective, but adverse reactions were common, and crizotinib was generally well-tolerated.

28 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Ramon Andrade Bezerra De MelloRamon Andrade Bezerra De Mello
Ramon Andrade Bezerra De Mello
RVRafael Voscaboinik
Rafael Voscaboinik
JLJoão Vittor Pires Luciano
João Vittor Pires Luciano
RCRafaela Vilela Cremonese
Rafaela Vilela Cremonese
Giovanna AmaralGiovanna Amaral
Giovanna Amaral
GAGeorgios Antoniou
Georgios Antoniou
From a complete literature review, we were able to present in this paper what is most current in the treatment with immunotherapy for advanced non-small cell lung cancer (NSCLC). Especially the use of immunotherapy, particularly inhibitors of PD-1 (programmed cell death protein 1), PDL-1 (programmed cell death protein ligand 1), and CTLA-4 (cytotoxic T-lymphocyte antigen 4). Since 2015, these drugs have transformed the treatment of advanced NSCLC lacking driver mutations, evolving from second-line therapy to first-line, with excellent results. The arrival of new checkpoint inhibitors such as cemiplimab and the use of checkpoint inhibitors earlier in the therapy of advanced and metastatic cancers has been making the future prospects for treating NSCLC lacking driver mutations more favorable and optimistic. In addition, for those patients who have low PDL-1 positivity tumors, the combination of cytotoxic chemotherapy, VEGF inhibitor, and immunotherapy have shown an important improvement in global survival and progression free survival regardless the PDL-1 status. We also explored the effectiveness of adding radiotherapy to immunotherapy and the most current results about this combination. One concern that cannot be overlooked is the safety profile of immune checkpoint inhibitors (ICI) and the most common toxicities are described throughout this paper as well as tumor resistance to ICI.

7 October 2021 in Medical Teacher
Verified
Journal Article
Closed access
EOElda de Oliveira
Elda de Oliveira
RDRafaela Gonçalves Dantas
Rafaela Gonçalves Dantas
Giovanna AmaralGiovanna Amaral
Giovanna Amaral
RGRenata Rocha Barreto Giaxa
Renata Rocha Barreto Giaxa
AGAécio Flávio Teixeira de Góis
Aécio Flávio Teixeira de Góis
Since people with disabilities (PwD) are underrepresented in medical education, the authors of this article conducted a qualitative research in the form of an in-depth interview with students with ...

7 April 2021 in Immunotherapy
Verified
Journal Article
Closed access
Ramon Andrade Bezerra De MelloRamon Andrade Bezerra De Mello
Ramon Andrade Bezerra De Mello
Giovanna AmaralGiovanna Amaral
Giovanna Amaral
CTCarla Chizuru Tajima
Carla Chizuru Tajima
HTHakaru Tadokoro
Hakaru Tadokoro
JIJairo Iavelberg
Jairo Iavelberg
JSJosé Antonio Silva
José Antonio Silva